Merck-Moderna Cancer Vaccine Scores Big in Late-Stage Trial

A groundbreaking cancer treatment has shown promising results in its first late-stage trial. The personalized vaccine, developed by Merck and Moderna, was tested on over 1,100 patients with higher-risk or advanced melanoma. When used alongside Merck's established immunotherapy Keytruda, the combination therapy successfully met its primary objectives.

The mRNA-based vaccine extended the duration patients lived without their melanoma returning and reduced the risk of metastasis to other parts of the body. This is a significant breakthrough in cancer treatment, particularly for melanoma, which accounts for a substantial majority of skin cancer-related deaths despite being relatively rare.

Merck's shares jumped over 8% in premarket trading following the announcement, while Moderna saw its stock surge by about 100%. The results build on encouraging phase two trial findings and pave the way for ongoing trials targeting various cancers. Dr. Jane Healy, head of oncology early development at Merck, highlighted the 'clinically meaningful improvement' over Keytruda and favorable tolerability of the treatment.

The personalized approach targets unique mutations present in each patient's tumor, enhancing the immune system's ability to recognize and attack cancer markers. This method is expected to work synergistically with Keytruda to boost the immune response against cancer. The advancements reflect a significant leap towards personalized medicine, with both Merck and Moderna at the forefront of this evolution in oncology.